ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 110 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8 | -74.2% | 1,987 | 0.0% | 0.00% | – |
| Q1 2024 | $31 | -75.4% | 1,987 | -76.0% | 0.00% | -100.0% |
| Q4 2023 | $126 | -25.9% | 8,296 | -2.2% | 0.00% | 0.0% |
| Q3 2023 | $170 | -19.4% | 8,484 | +13.5% | 0.00% | -50.0% |
| Q2 2023 | $211 | +88.4% | 7,473 | +14.5% | 0.00% | +100.0% |
| Q1 2023 | $112 | -25.8% | 6,526 | -12.8% | 0.00% | 0.0% |
| Q4 2022 | $151 | -99.9% | 7,481 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $162,000 | -4.1% | 7,481 | +24.1% | 0.00% | 0.0% |
| Q2 2022 | $169,000 | -38.3% | 6,026 | +1.4% | 0.00% | 0.0% |
| Q1 2022 | $274,000 | -74.5% | 5,945 | -53.5% | 0.00% | -50.0% |
| Q4 2021 | $1,074,000 | +152.7% | 12,774 | +100.2% | 0.00% | 0.0% |
| Q3 2021 | $425,000 | +27.2% | 6,381 | +1.6% | 0.00% | +33.3% |
| Q2 2021 | $334,000 | +55.3% | 6,278 | +51.4% | 0.00% | -62.5% |
| Q4 2020 | $215,000 | – | 4,148 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
| Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
| Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
| 5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
| Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
| Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
| First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
| Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |